Even the best cancer treatments that remove the bulk of a tumour will rarely eradicate 100% of malignant cells. Any missed cells can remain active and pose a risk of relapse, but are often present in ...

The market for breast cancer liquid biopsy testing devices offers significant opportunities driven by rising breast cancer incidence and demand for non-invasive, frequent genomic profiling solutions.

The RNA analysis market is poised for significant growth due to rising demand in precision medicine, advancements in NGS technologies, and expanding use of RNA biomarkers in diagnostics and drug ...